Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00651508 | Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | PHASE2 | COMPLETED | 1 | — | — | Apr 1, 2008 | Oct 1, 2008 | May 17, 2016 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Single Arm 25mg/m2 | EXPERIMENTAL | KOS-1584 25mg/m2 |
| Name | Type | Description |
|---|---|---|
| KOS-1584 | DRUG | 25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops. |
Inclusion Criteria: * Histologically or cytologically proven NSCLC, Stage IIIB or Stage IV. * Eligible patients must have received only one prior chemotherapy regime for Stage IIIB/IV NSCLC. * Good performance status. Exclusion Criteria: * Prior treatment with an epothilone. * Known central nervo...